A detailed competitor profile identifying entities from discovery through final approval involved speaking with chemists, spectroscopy scientists, genomic scientists, regulatory authorities, pharmacists, drug information personnel, chemical entity formulators and clinicians.
Primary Impact's report revealed that two drugs were close to commercialization and would be offered in patches and capsules. We also identified that six potential breakthroughs occurred after their genomics laboratory identified only a handful of genes responsible for specific therapeutic conditions. These six were in the process of moving into the compound profiling department.
Competitive Consulting
Understanding the status of new chemical entities and compounds to be released within (18) months helped to prepare a competitive strategy to address pharmaceuticals which would be soon released. Knowing their competitive pipeline also helped during internal planning sessions with Research and Development. Click to learn more about Primary Impact's pharmaceutical industry practice.
